Your browser doesn't support javascript.
Successful use of ketamine to treat severe depression with suicidality post-COVID-19 - A case report.
Meha, Sharma; Suhas, Satish; Rao, Naren P.
  • Meha S; Department of Psychiatry, National Institute of Mental Health and Neurosciences, Bangalore, India.
  • Suhas S; Department of Psychiatry, National Institute of Mental Health and Neurosciences, Bangalore, India.
  • Rao NP; Department of Psychiatry, National Institute of Mental Health and Neurosciences, Bangalore, India.
Psychiatry Res Case Rep ; 2(1): 100100, 2023 Jun.
Article in English | MEDLINE | ID: covidwho-2165776
ABSTRACT
Every second patient who suffers from COVID-19 experiences is at risk for depression. The treatment of severe depression with suicidal risk is challenging in patients with COVID-19 given the restrictions in access to and safety concerns with the use of electroconvulsive therapy during the COVID pandemic. Although ketamine is effective in treating depression, especially in presence of acute suicidality, to date, there are no reports on ketamine use to treat severe depression in the context of COVID-19. In this case report, we describe the success of ketamine to treat a person with severe depression and suicidality following COVID-19 infection.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Case report / Prognostic study / Qualitative research Topics: Long Covid Language: English Journal: Psychiatry Res Case Rep Year: 2023 Document Type: Article Affiliation country: J.psycr.2022.100100

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Case report / Prognostic study / Qualitative research Topics: Long Covid Language: English Journal: Psychiatry Res Case Rep Year: 2023 Document Type: Article Affiliation country: J.psycr.2022.100100